SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a preliminary (unaudited) estimate of net product revenue from sales of OFIRMEV® (acetaminophen) injection for the three-months ended December 31, 2012, of approximately $17.1 million.
"We ended 2012 on a high note, with fourth quarter revenues exceeding the guidance given in our announcement of our third quarter 2012 financial results," said Ted Schroeder , President and CEO of Cadence. "We believe that our strategy to increase access to OFIRMEV within the hospital and to build awareness of the product's utility in multi-modal pain management has resulted in growing sales, and we look forward to continuing this momentum in 2013."
As of January 23, 2013, Cadence expects that net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2013, will range from approximately $94.0 million to $100.0 million.
A more complete discussion of Cadence's financial results for the year ended December 31, 2012, will occur during the Company's regularly scheduled quarterly conference call.
About OFIRMEV® (Acetaminophen) Injection
OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved